-
1
-
-
84907661954
-
Industry sponsorship bias in research findings: A network meta-analysis of LDL cholesterol reduction in randomised trials of statins
-
Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014;349:g5741.
-
(2014)
BMJ
, vol.349
, pp. g5741
-
-
Naci, H.1
Dias, S.2
Ades, A.E.3
-
2
-
-
34347243202
-
Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others
-
Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLOS Med 2007;4:e184.
-
(2007)
PLOS Med
, vol.4
, pp. e184
-
-
Bero, L.1
Oostvogel, F.2
Bacchetti, P.3
Lee, K.4
-
4
-
-
0028115828
-
A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
-
Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
-
(1994)
Arch Intern Med
, vol.154
, pp. 157-163
-
-
Rochon, P.A.1
Gurwitz, J.H.2
Simms, R.W.3
Fortin, P.R.4
Felson, D.T.5
Minaker, K.L.6
-
5
-
-
33644994132
-
Why olazepine beats risperidone, risperidone beats quetiapine, and quetiapine beats olazepine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics
-
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olazepine beats risperidone, risperidone beats quetiapine, and quetiapine beats olazepine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
-
(2006)
Am J Psychiatry
, vol.163
, pp. 185-194
-
-
Heres, S.1
Davis, J.2
Maino, K.3
Jetzinger, E.4
Kissling, W.5
Leucht, S.6
-
6
-
-
0036742342
-
Design and reporting modifications in industry sponsored comparative psychopharmacology trials
-
Safer DJ. Design and reporting modifications in industry sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
-
(2002)
J Nerv Ment Dis
, vol.190
, pp. 583-592
-
-
Safer, D.J.1
-
7
-
-
0033544292
-
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis
-
Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
-
(1999)
JAMA
, vol.282
, pp. 1752-1759
-
-
Johansen, H.K.1
Gøtzsche, P.C.2
-
8
-
-
42249100174
-
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation
-
Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008;299:1813-7.
-
(2008)
JAMA
, vol.299
, pp. 1813-1817
-
-
Psaty, B.M.1
Kronmal, R.A.2
-
9
-
-
70049099036
-
Chapter 8: Assessing risk of bias in included studies
-
Higgins JPT, Green S, eds
-
Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration, 2011.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration
-
-
Higgins, J.P.T.1
Altman, D.G.2
Sterne, J.A.C.3
-
10
-
-
84872362858
-
Industry sponsorship and research outcome
-
MR000033
-
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
-
(2012)
Cochrane Database Syst Rev
, vol.12
-
-
Lundh, A.1
Sismondo, S.2
Lexchin, J.3
Busuioc, O.A.4
Bero, L.5
-
11
-
-
84858996695
-
Effect of reporting bias on meta-analyses of drug trials: Reanalysis of meta-analyses
-
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;343:d7202.
-
(2012)
BMJ
, vol.343
, pp. d7202
-
-
Hart, B.1
Lundh, A.2
Bero, L.3
-
12
-
-
84897368196
-
Why the Cochrane risk of bias tool should include funding source as a standard item[editorial]
-
ED000075
-
Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database Syst Rev 2013;12:ED000075.
-
(2013)
Cochrane Database Syst Rev
, vol.12
-
-
Bero, L.A.1
-
13
-
-
84866146413
-
Corporate manipulation of research: Strategies are similar across five industries
-
White J, Bero LA. Corporate manipulation of research: strategies are similar across five industries. Stanford Law Policy Rev 2010;21:105-34.
-
(2010)
Stanford Law Policy Rev
, vol.21
, pp. 105-134
-
-
White, J.1
Bero, L.A.2
|